GlassScriptPhysician profile
Margaret Hebert
NPI 1073018024
$2,737.82
in general payments reported to CMS, 2019-2025
28 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $362 · 2023: $726 · 2024: $673 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $629.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $293.14 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $194.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $186.68 | 2023-2025 | |
| Exact Sciences Corporation | $164.11 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $142.43 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $130.96 | 2022-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $125.58 | 2021-2025 | Trintellix |
| Amgen INC. | $115.34 | 2023-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $105.35 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.15 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $81.04 | 2021-2025 | |
| Axsome Therapeutics, INC. | $75.91 | 2025 | Auvelity |
| Abbott Laboratories | $71.45 | 2023-2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $36.87 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $33.52 | 2024-2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2021-2022 | |
| Neos Therapeutics, LP | $30.41 | 2024 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $30.30 | 2022-2023 | |
| Corium, LLC | $23.78 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $22.54 | 2025 | Camzyos |
| Esperion Therapeutics, INC. | $20.84 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.23 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $18.99 | 2025 | Voquezna |
| Dexcom, INC. | $18.21 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $16.74 | 2023 | |
| Merck Sharp & Dohme LLC | $16.33 | 2025 | Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $14.30 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.